Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age80+
SponsorFirst Affiliated Hospital of Guangxi Medical University
About this trial
The benefit of intravenous tenecteplase in very old patients with acute ischemic stroke (AIS) remain uncertain. This real-world study aims to evaluate the effectiveness and safety of intravenous tenecteplase in AIS patients aged 80 years or older within 4.5 hours of symptom onset.
Eligibility criteria
Qualifiers
Age > 80 years;
Clinically diagnosed with acute ischemic stroke and arrived at the hospital within 4.5 hours of symptom onset;
Informed consent signed by the patient or legally authorized representative.
Disqualifiers
Any contraindication to intravenous thrombolysis (excluding age);
Previous treatment with other thrombolytic agents such as alteplase, urokinase, plasminogen activator, or reteplase;
Current participation in other interventional studies;
The investigator deems the patient unsuitable for this study or the study might pose significant risk to the patient (e.g., due to psychiatric disorders, cognitive or emotional impairments that prevent understanding or adherence to study procedures and/or follow-up).
Trial design
Treatments tested in this trial
- Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Standard medical care
Treatment groups
392 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov